Identification

Name
Vecuronium
Accession Number
DB01339
Type
Small Molecule
Groups
Approved
Description

Monoquaternary homolog of pancuronium. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.

Structure
Thumb
Synonyms
  • Vecuronium cation
Product Ingredients
IngredientUNIICASInChI Key
Vecuronium bromide7E4PHP5N1D50700-72-6VEPSYABRBFXYIB-PWXDFCLTSA-M
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Norcuron Inj 10mg/vialPowder, for solution10 mgIntravenousOrganon Canada Ltd Ltee1986-12-312009-08-04Canada
Vecuronium Bromide for InjectionPowder, for solution10 mgIntravenousPartners Health Care, Inc.2000-06-132008-02-15Canada
Vecuronium Bromide for InjectionPowder, for solution10.00 mgIntravenousHospira, Inc.2000-06-01Not applicableCanada
Vecuronium Bromide for InjectionPowder, for solution20.00 mgIntravenousHospira, Inc.2000-01-28Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
VecuroniumInjection, powder, lyophilized, for solution20 mg/20mLIntravenousSagent Pharmaceuticals2011-08-01Not applicableUs
VecuroniumInjection, powder, lyophilized, for solution10 mg/10mLIntravenousSagent Pharmaceuticals2011-08-01Not applicableUs
Vecuronium BromideInjection, powder, lyophilized, for solution1 mg/mLIntravenousMylan Institutional2011-05-11Not applicableUs
Vecuronium BromideInjection, powder, lyophilized, for solution10 mg/10mLIntravenousCardinal Health1999-08-252017-10-26Us
Vecuronium BromideInjection, powder, lyophilized, for solution1 mg/mLIntravenousHospira, Inc.1999-10-21Not applicableUs
Vecuronium bromideInjection, powder, lyophilized, for solution1 mg/mLIntravenousAkorn Strides Llc2010-09-15Not applicableUs
Vecuronium BromideInjection, powder, lyophilized, for solution1 mg/mLIntravenousSun Pharma Global FZE2014-12-15Not applicableUs
Vecuronium BromideInjection, powder, lyophilized, for solution1 mg/mLIntravenousFresenius Kabi2016-06-30Not applicableUs
Vecuronium BromideInjection, powder, lyophilized, for solution1 mg/mLIntravenousGland Pharma Limited2016-06-30Not applicableUs
Vecuronium BromideInjection, powder, lyophilized, for solution1 mg/mLIntravenousRemedy Repack2015-06-232017-09-01Us
Categories
UNII
5438723848
CAS number
86029-43-8
Weight
Average: 557.8274
Monoisotopic: 557.431833322
Chemical Formula
C34H57N2O4
InChI Key
BGSZAXLLHYERSY-XQIGCQGXSA-N
InChI
InChI=1S/C34H57N2O4/c1-23(37)39-31-20-25-12-13-26-27(34(25,4)22-29(31)35-16-8-6-9-17-35)14-15-33(3)28(26)21-30(32(33)40-24(2)38)36(5)18-10-7-11-19-36/h25-32H,6-22H2,1-5H3/q+1/t25-,26+,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1
IUPAC Name
1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5,14-bis(acetyloxy)-2,15-dimethyl-4-(piperidin-1-yl)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-13-yl]-1-methylpiperidin-1-ium
SMILES
[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1

Pharmacology

Indication

Vecuronium is a muscle relaxing agent and is used as an ajunct in general anesthesia.

Associated Therapies
Pharmacodynamics

Vecuronium operates by competing for the cholinoceptors at the motor end plate thereby exerting its muscle-relaxing properties which are used adjunctively to general anesthesia.

Mechanism of action

Vecuronium is a bisquaternary nitrogen compound that acts by competitively binding to nicotinic cholinergic receptors. The binding of vecuronium decreases the opportunity for acetylcholine to bind to the nicotinic receptor at the postjunctional membrane of the myoneural junction. As a result, depolarization is prevented, calcium ions are not released and muscle contraction does not occur.

TargetActionsOrganism
ANeuronal acetylcholine receptor subunit alpha-2
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

100%

Route of elimination

Fecal (40-75%) and renal (30% as unchanged drug and metabolites)

Half life

51–80 minutes

Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AcetyldigitoxinVecuronium may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AcetyldigoxinVecuronium may increase the arrhythmogenic activities of Acetyldigoxin.Experimental
AclidiniumVecuronium may increase the anticholinergic activities of Aclidinium.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Alcuronium.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Vecuronium is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Vecuronium is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Alphaprodine.Illicit
AmbenoniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Ambenonium.Approved
AmikacinAmikacin may increase the respiratory depressant activities of Vecuronium.Approved, Investigational, Vet Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Vecuronium.Approved
ApalutamideThe serum concentration of Vecuronium can be decreased when it is combined with Apalutamide.Approved, Investigational
ApramycinApramycin may increase the respiratory depressant activities of Vecuronium.Experimental, Vet Approved
ArbekacinArbekacin may increase the respiratory depressant activities of Vecuronium.Approved, Investigational
AtracuriumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Atracurium.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Vecuronium.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Vecuronium.Approved, Vet Approved
AzosemideAzosemide may decrease the neuromuscular blocking activities of Vecuronium.Investigational
BekanamycinBekanamycin may increase the respiratory depressant activities of Vecuronium.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Vecuronium.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Vecuronium.Approved
BenzthiazideThe serum concentration of Benzthiazide can be increased when it is combined with Vecuronium.Approved
BezitramideThe risk or severity of adverse effects can be increased when Vecuronium is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Vecuronium.Approved, Investigational
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Vecuronium.Experimental
Botulinum Toxin Type ABotulinum Toxin Type A may increase the neuromuscular blocking activities of Vecuronium.Approved, Investigational
Botulinum Toxin Type BVecuronium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved, Investigational
BumetanideBumetanide may decrease the neuromuscular blocking activities of Vecuronium.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Vecuronium is combined with Butorphanol.Approved, Illicit, Vet Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Butylscopolamine.Approved, Investigational, Vet Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Vecuronium.Approved
CarbamazepineThe serum concentration of Vecuronium can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Vecuronium is combined with Carfentanil.Illicit, Investigational, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Vecuronium.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Chlorphenoxamine.Withdrawn
ChlortetracyclineChlortetracycline may increase the neuromuscular blocking activities of Vecuronium.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may decrease the neuromuscular blocking activities of Vecuronium.Approved
CimetropiumVecuronium may increase the anticholinergic activities of Cimetropium.Experimental, Investigational
ClindamycinClindamycin may increase the neuromuscular blocking activities of Vecuronium.Approved, Vet Approved
CodeineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Codeine.Approved, Illicit
ColistimethateColistimethate may increase the neuromuscular blocking activities of Vecuronium.Approved, Vet Approved
CoumaphosThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Coumaphos.Vet Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Vecuronium.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Vecuronium.Approved
CyclosporineCyclosporine may increase the neuromuscular blocking activities of Vecuronium.Approved, Investigational, Vet Approved
CymarinVecuronium may increase the arrhythmogenic activities of Cymarin.Experimental
DantroleneDantrolene may increase the neuromuscular blocking activities of Vecuronium.Approved, Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Vecuronium.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Demecarium.Approved
DemeclocyclineDemeclocycline may increase the neuromuscular blocking activities of Vecuronium.Approved
DeslanosideVecuronium may increase the arrhythmogenic activities of Deslanoside.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Vecuronium.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Vecuronium.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dezocine.Approved, Investigational
DibekacinDibekacin may increase the respiratory depressant activities of Vecuronium.Experimental
DichlorvosThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Vecuronium.Approved
DigitoxinVecuronium may increase the arrhythmogenic activities of Digitoxin.Approved, Investigational
DigoxinVecuronium may increase the arrhythmogenic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Vecuronium may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinDihydrostreptomycin may increase the respiratory depressant activities of Vecuronium.Investigational, Vet Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Vecuronium.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Vecuronium is combined with Diphenoxylate.Approved, Illicit
DipivefrinThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Dipivefrin.Approved
DistigmineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Distigmine.Experimental
DonepezilThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Donepezil.Approved
DoxycyclineDoxycycline may increase the neuromuscular blocking activities of Vecuronium.Approved, Investigational, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Vecuronium is combined with DPDPE.Experimental
DronabinolVecuronium may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Edrophonium.Approved
EluxadolineVecuronium may increase the constipating activities of Eluxadoline.Approved, Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Emepronium.Experimental
EpitizideThe serum concentration of Epitizide can be increased when it is combined with Vecuronium.Experimental
Etacrynic acidEtacrynic acid may decrease the neuromuscular blocking activities of Vecuronium.Approved, Investigational
EtanautineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Etanautine.Experimental
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Vecuronium.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Etybenzatropine.Experimental
FentanylThe risk or severity of adverse effects can be increased when Vecuronium is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Fesoterodine.Approved
FlavoxateThe risk or severity of adverse effects can be increased when Flavoxate is combined with Vecuronium.Approved
FramycetinFramycetin may increase the respiratory depressant activities of Vecuronium.Approved
FurosemideFurosemide may decrease the neuromuscular blocking activities of Vecuronium.Approved, Vet Approved
GalantamineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Vecuronium.Approved
GeneticinGeneticin may increase the respiratory depressant activities of Vecuronium.Experimental
GentamicinGentamicin may increase the respiratory depressant activities of Vecuronium.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the respiratory depressant activities of Vecuronium.Experimental
Ginkgo bilobaThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Ginkgo biloba.Approved, Investigational, Nutraceutical
GitoformateVecuronium may increase the arrhythmogenic activities of Gitoformate.Experimental
Glucagon recombinantThe risk or severity of adverse effects can be increased when Vecuronium is combined with Glucagon recombinant.Approved
GlycopyrroniumVecuronium may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Vecuronium is combined with Heroin.Approved, Illicit, Investigational
HomatropineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Homatropine.Approved
Human secretinThe therapeutic efficacy of Human secretin can be decreased when used in combination with Vecuronium.Approved
Huperzine AThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Huperzine A.Approved, Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Vecuronium.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Vecuronium is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideHydroflumethiazide may decrease the neuromuscular blocking activities of Vecuronium.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Vecuronium is combined with Hydromorphone.Approved, Illicit
Hygromycin BHygromycin B may increase the respiratory depressant activities of Vecuronium.Vet Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Vecuronium.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Vecuronium.Approved
IpidacrineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Ipidacrine.Experimental
IpratropiumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Vecuronium.Approved
IsavuconazoleThe serum concentration of Vecuronium can be increased when it is combined with Isavuconazole.Approved, Investigational
IsepamicinIsepamicin may increase the respiratory depressant activities of Vecuronium.Experimental
IsoflurophateThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Vecuronium.Investigational
KanamycinKanamycin may increase the respiratory depressant activities of Vecuronium.Approved, Investigational, Vet Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Vecuronium is combined with Ketobemidone.Approved, Investigational
Lanatoside CVecuronium may increase the arrhythmogenic activities of Lanatoside C.Experimental
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Vecuronium is combined with Levomethadyl Acetate.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Vecuronium is combined with Levorphanol.Approved
LincomycinLincomycin may increase the neuromuscular blocking activities of Vecuronium.Approved, Vet Approved
Lithium cationLithium may increase the neuromuscular blocking activities of Vecuronium.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Vecuronium is combined with Lofentanil.Illicit
LorpiprazoleThe therapeutic efficacy of Vecuronium can be increased when used in combination with Lorpiprazole.Approved
LumacaftorThe serum concentration of Vecuronium can be decreased when it is combined with Lumacaftor.Approved
Magnesium hydroxideMagnesium hydroxide may increase the neuromuscular blocking activities of Vecuronium.Approved, Investigational
Magnesium oxideMagnesium oxide may increase the neuromuscular blocking activities of Vecuronium.Approved
Magnesium salicylateMagnesium salicylate may increase the neuromuscular blocking activities of Vecuronium.Approved
Magnesium sulfateMagnesium sulfate may increase the neuromuscular blocking activities of Vecuronium.Approved, Investigational, Vet Approved
MalathionThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Malathion.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Vecuronium is combined with Mazaticol.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Vecuronium.Approved, Investigational
MefloquineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Mefloquine.Approved, Investigational
MemantineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Memantine.Approved, Investigational
MeptazinolThe risk or severity of adverse effects can be increased when Vecuronium is combined with Meptazinol.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Vecuronium is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Vecuronium is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Vecuronium.Approved, Investigational
MethscopolamineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Methscopolamine.Approved
MethyclothiazideMethyclothiazide may decrease the neuromuscular blocking activities of Vecuronium.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Vecuronium is combined with Methylscopolamine bromide.Approved
MetildigoxinVecuronium may increase the arrhythmogenic activities of Metildigoxin.Experimental
MetixeneThe risk or severity of adverse effects can be increased when Vecuronium is combined with Metixene.Approved
MetoclopramideThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Vecuronium.Approved
MianserinMianserin may increase the anticholinergic activities of Vecuronium.Approved, Investigational
MicronomicinMicronomicin may increase the respiratory depressant activities of Vecuronium.Experimental
MinaprineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Minaprine.Approved
MinocyclineMinocycline may increase the neuromuscular blocking activities of Vecuronium.Approved, Investigational
MirabegronThe risk or severity of adverse effects can be increased when Vecuronium is combined with Mirabegron.Approved
MorphineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Morphine.Approved, Investigational
NabiloneVecuronium may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Nalbuphine.Approved
NeamineNeamine may increase the respiratory depressant activities of Vecuronium.Experimental
NeomycinNeomycin may increase the respiratory depressant activities of Vecuronium.Approved, Vet Approved
NeostigmineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NetilmicinNetilmicin may increase the respiratory depressant activities of Vecuronium.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Nicomorphine.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Vecuronium is combined with Normethadone.Approved, Illicit
OleandrinVecuronium may increase the arrhythmogenic activities of Oleandrin.Experimental, Investigational
OpiumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Vecuronium.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Otilonium.Experimental, Investigational
OuabainVecuronium may increase the arrhythmogenic activities of Ouabain.Approved
OxitropiumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Oxitropium.Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Vecuronium.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Vecuronium is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Vecuronium is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Vecuronium.Approved
OxytetracyclineOxytetracycline may increase the neuromuscular blocking activities of Vecuronium.Approved, Investigational, Vet Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Vecuronium.Approved
ParaoxonThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Paraoxon.Experimental
ParomomycinParomomycin may increase the respiratory depressant activities of Vecuronium.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Vecuronium.Approved
PeruvosideVecuronium may increase the arrhythmogenic activities of Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Phenazocine.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Vecuronium.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Phenoperidine.Experimental
PhysostigmineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Physostigmine.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Vecuronium.Approved
PiperacillinPiperacillin may increase the neuromuscular blocking activities of Vecuronium.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Vecuronium.Approved
PiretanidePiretanide may decrease the neuromuscular blocking activities of Vecuronium.Approved
PiritramideThe risk or severity of adverse effects can be increased when Vecuronium is combined with Piritramide.Approved, Investigational
PirlimycinPirlimycin may increase the neuromuscular blocking activities of Vecuronium.Vet Approved
PitolisantThe serum concentration of Vecuronium can be decreased when it is combined with Pitolisant.Approved, Investigational
PlazomicinPlazomicin may increase the respiratory depressant activities of Vecuronium.Approved, Investigational
Polymyxin B SulfatePolymyxin B Sulfate may increase the neuromuscular blocking activities of Vecuronium.Approved, Vet Approved
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Vecuronium.Approved
Potassium ChlorideVecuronium may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Vecuronium.Approved, Investigational
ProcainamideProcainamide may increase the neuromuscular blocking activities of Vecuronium.Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Vecuronium.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Vecuronium.Approved
PropiverineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Propiverine.Approved, Investigational
ProscillaridinVecuronium may increase the arrhythmogenic activities of Proscillaridin.Experimental
PuromycinPuromycin may increase the respiratory depressant activities of Vecuronium.Experimental
PyridostigmineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Pyridostigmine.Approved, Investigational
QuinethazoneQuinethazone may decrease the neuromuscular blocking activities of Vecuronium.Approved
QuinidineQuinidine may increase the neuromuscular blocking activities of Vecuronium.Approved, Investigational
QuinineQuinine may increase the neuromuscular blocking activities of Vecuronium.Approved
RamosetronVecuronium may increase the constipating activities of Ramosetron.Approved, Investigational
RanolazineThe serum concentration of Vecuronium can be increased when it is combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Vecuronium is combined with Remifentanil.Approved
RibostamycinRibostamycin may increase the respiratory depressant activities of Vecuronium.Approved, Investigational
RivastigmineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Rivastigmine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Vecuronium.Approved, Investigational
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Vecuronium.Approved, Investigational
SisomicinSisomicin may increase the respiratory depressant activities of Vecuronium.Investigational
SolifenacinThe risk or severity of adverse effects can be increased when Vecuronium is combined with Solifenacin.Approved
StreptomycinStreptomycin may increase the respiratory depressant activities of Vecuronium.Approved, Vet Approved
SufentanilThe risk or severity of adverse effects can be increased when Vecuronium is combined with Sufentanil.Approved, Investigational
SulpirideVecuronium may increase the anticholinergic activities of Sulpiride.Approved, Investigational
TacrineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Tacrine.Investigational, Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Vecuronium is combined with Tapentadol.Approved
TetracyclineTetracycline may increase the neuromuscular blocking activities of Vecuronium.Approved, Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Tilidine.Experimental
TiotropiumVecuronium may increase the anticholinergic activities of Tiotropium.Approved
TobramycinTobramycin may increase the respiratory depressant activities of Vecuronium.Approved, Investigational
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Vecuronium.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Vecuronium is combined with Topiramate.Approved
TorasemideTorasemide may decrease the neuromuscular blocking activities of Vecuronium.Approved
TramadolThe risk or severity of adverse effects can be increased when Vecuronium is combined with Tramadol.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideTrichlormethiazide may decrease the neuromuscular blocking activities of Vecuronium.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Vecuronium.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Vecuronium.Approved, Investigational
TropatepineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Vecuronium.Approved, Investigational
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Vecuronium.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Vecuronium.Approved
TyrothricinThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Tyrothricin.Approved
UmeclidiniumVecuronium may increase the anticholinergic activities of Umeclidinium.Approved
VancomycinVancomycin may increase the neuromuscular blocking activities of Vecuronium.Approved
VemurafenibThe serum concentration of Vecuronium can be increased when it is combined with Vemurafenib.Approved
Food Interactions
Not Available

References

Synthesis Reference

Frans Herwig Jan Jansen, "Process to prepare pharmaceutical compositions containing vecuronium bromide and compositions produced thereby." U.S. Patent US5681573, issued January, 1969.

US5681573
General References
Not Available
External Links
Human Metabolome Database
HMDB0015432
KEGG Compound
C07553
PubChem Compound
39765
PubChem Substance
46507656
ChemSpider
36358
BindingDB
50424713
ChEBI
9939
ChEMBL
CHEMBL1201219
Therapeutic Targets Database
DAP000354
PharmGKB
PA164748865
IUPHAR
4002
Guide to Pharmacology
GtP Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Vecuronium
ATC Codes
M03AC03 — Vecuronium
AHFS Codes
  • 12:20.20 — Neuromuscular Blocking Agents

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedOtherArthropathy of Hip1
4CompletedTreatmentAnaesthesia therapy1
4CompletedTreatmentGall Stone Disease1
4Not Yet RecruitingOtherPatients Undergoing Laparoscopic Surgery1
4Unknown StatusTreatmentPerioperative/Postoperative Complications / PORC (Postoperative Residual Curarization)1
Not AvailableCompletedSupportive CareC.Delivery; Surgery (Previous), Gynecological / Delayed Emergence From Anesthesia / Inappropriate Device Stimulation of Tissue1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • APP Pharmaceuticals
  • Baxter International Inc.
  • Bedford Labs
  • Ben Venue Laboratories Inc.
  • Cardinal Health
  • Hospira Inc.
  • Organon Pharmaceuticals
  • Pharmedium
  • Schein Pharmaceutical Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Watson Pharmaceuticals
  • Zhejiang Xianju Pharmaceutical Co. Ltd.
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntravenous10 mg/10mL
Injection, powder, lyophilized, for solutionIntravenous20 mg/20mL
Injection, powder, lyophilized, for solutionIntravenous1 mg/mL
Powder, for solutionIntravenous10 mg
Powder, for solutionIntravenous10.00 mg
Powder, for solutionIntravenous20.00 mg
Prices
Unit descriptionCostUnit
Vecuronium 20 mg vial5.05USD vial
Vecuronium 10 mg vial3.64USD vial
Vecuronium 10 mg/10 ml syringe2.36USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)228 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility1.86e-05 mg/mLALOGPS
logP2.07ALOGPS
logP0.89ChemAxon
logS-7.5ALOGPS
pKa (Strongest Basic)9.65ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area55.84 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity169.31 m3·mol-1ChemAxon
Polarizability66.85 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8913
Blood Brain Barrier+0.878
Caco-2 permeable+0.5457
P-glycoprotein substrateSubstrate0.77
P-glycoprotein inhibitor IInhibitor0.6962
P-glycoprotein inhibitor IIInhibitor0.6508
Renal organic cation transporterNon-inhibitor0.6862
CYP450 2C9 substrateNon-substrate0.8382
CYP450 2D6 substrateNon-substrate0.7638
CYP450 3A4 substrateSubstrate0.742
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9229
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9368
Ames testNon AMES toxic0.7499
CarcinogenicityNon-carcinogens0.9265
BiodegradationNot ready biodegradable0.8557
Rat acute toxicity2.6653 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9021
hERG inhibition (predictor II)Non-inhibitor0.7784
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0000090000-30783b30128b3c20c2ae
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0000090000-cd687d0e7ce4ae357aff
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0101090000-89eda364a0ed6638a666
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0pb9-1809120000-c2bee4083e6bf7f417b3
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0zfr-2904000000-2c0dfbec678d7b580771

Taxonomy

Description
This compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Steroid esters
Direct Parent
Steroid esters
Alternative Parents
Androstane steroids / Piperidines / Dicarboxylic acids and derivatives / Tetraalkylammonium salts / Trialkylamines / Carboxylic acid esters / Amino acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organic salts
show 4 more
Substituents
Steroid ester / Androstane-skeleton / Dicarboxylic acid or derivatives / Piperidine / Quaternary ammonium salt / Tetraalkylammonium salt / Amino acid or derivatives / Carboxylic acid ester / Tertiary amine / Tertiary aliphatic amine
show 15 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
quaternary ammonium ion, acetate ester, androstane (CHEBI:9939)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Drug binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA2
Uniprot ID
Q15822
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-2
Molecular Weight
59764.82 Da
References
  1. Jonsson Fagerlund M, Dabrowski M, Eriksson LI: Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. doi: 10.1097/ALN.0b013e31819fade3. [PubMed:19417616]
  2. Liu M, Dilger JP: Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg. 2008 Aug;107(2):525-33. doi: 10.1213/ane.0b013e31817b4469. [PubMed:18633030]
  3. Paul M, Fokt RM, Kindler CH, Dipp NC, Yost CS: Characterization of the interactions between volatile anesthetics and neuromuscular blockers at the muscle nicotinic acetylcholine receptor. Anesth Analg. 2002 Aug;95(2):362-7, table of contents. [PubMed:12145052]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM: Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997 Jun;51(6):913-21. [PubMed:9187257]
  2. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Smit JW, Weert B, Schinkel AH, Meijer DK: Heterologous expression of various P-glycoproteins in polarized epithelial cells induces directional transport of small (type 1) and bulky (type 2) cationic drugs. J Pharmacol Exp Ther. 1998 Jul;286(1):321-7. [PubMed:9655875]

Drug created on June 30, 2007 12:08 / Updated on July 13, 2018 01:08